Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
The future of multiple myeloma is personalised, but we must work together to deliver it
Myeloma remains incurable, with treatment resistance increasing with each relapse. Personalised therapies are crucial due to myeloma's heterogeneity. Clinical trials must diversify to represent all patient populations, addressing ethnic disparities. Real-world evidence is essential for personalised care, requiring standardised collection and assessment methods. Patient needs should drive R&D, ensuring treatments are practical and effective.
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
Johnson & Johnson reported strong Q3 2024 results with 6.3% operational sales growth, driven by high-innovation and high-growth markets. Key achievements include FDA approvals for Rybrevant and Tremfya, significant sales from Darzalex and Carvykti, and strategic acquisitions like Shockwave and V-Wave. Despite challenges in Asia-Pacific, the company remains confident in its growth trajectory and has increased its 2024 financial guidance.
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Potential
BofA Securities upgraded Tyra Biosciences to Buy, citing TYRA-300's preclinical success in treating hypochondroplasia and its potential in urothelial carcinoma. With a new price target of $31, BofA highlights TYRA-300's safety profile and projects 2030 sales for metastatic urothelial carcinoma at $175M.
The number of AI medical devices has spiked in the past
The FDA has authorized 950 AI/ML-enabled medical devices by Aug. 7, 2024, with a significant increase from 6 in 2015 to 221 in 2023. Radiology dominates, but expansion into cardiovascular and other specialties is growing. GE Healthcare and Siemens Healthineers lead in AI device authorization. Most devices are cleared via the FDA's 510(k) pathway, indicating a trend towards faster, less rigorous approvals.
Johnson & Johnson submits new Monarch surgical robot software for FDA clearance
Johnson & Johnson MedTech filed an FDA 510(k) submission for the latest Monarch platform software release, designed for bronchoscopic visualization and access to adult patient airways, enabling minimally invasive, robotic-assisted technology for peripheral lung procedures.
J&J seeks new FDA approval of Darzalex Faspro myeloma combo
Johnson & Johnson seeks FDA approval for Darzalex Faspro-based quadruple regimen for newly diagnosed multiple myeloma patients not initially planning stem cell transplant. The D-VRd combo, already approved for transplant-eligible patients, showed significant benefits in the CEPHEUS trial, including higher MRD-negativity rates and reduced disease progression risk.
Related Clinical Trials:
Distinct Alzheimer Disease Subtypes Using Proteomic Fingerprints: Fiona Elwood, PhD
Alzheimer's disease subtypes identified through CSF proteomics data: (1) neuronal plasticity, (2) innate immunity, (3) blood-brain barrier dysfunction. These subtypes highlight the need for precision medicine in AD treatment.
Phase 3 Study of TAR-200/Cetrelimab Is Discontinued in MIBC
Johnson & Johnson halts phase 3 SunRISe-2 trial evaluating TAR-200 and cetrelimab vs chemoradiation for muscle-invasive bladder cancer (MIBC) patients not undergoing radical cystectomy, following an interim analysis. The company remains confident in TAR-200's potential, with ongoing studies and an FDA filing planned for early 2025.
Related Clinical Trials:
Johnson & Johnson discontinues Phase III study of treatment for bladder cancer
Johnson & Johnson discontinued SunRISe-2 study for TAR-200 in MIBC patients not undergoing radical cystectomy after interim analysis showed no superiority to chemoradiation. However, potential for TAR-200 is seen in SunRISe-4 study, with plans for FDA filing of TAR-200 monotherapy based on SunRISe-1 trial data.
© Copyright 2025. All Rights Reserved by MedPath